Psoriasis Therapy in Real Life: The Need for Registries
- 1 November 2006
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 213 (4) , 327-330
- https://doi.org/10.1159/000096196
Abstract
The introduction of new therapeutic options for the management of psoriasis is a challenge for the dermatology community, and new tools are needed to face this challenge. This article argues for the establishment of profession-based registries to collect solid, long-term data on the safety and effectiveness of different psoriasis treatment regimens. Managed by health care professionals, registries will be most successful if they enroll patients based on indications for treatment rather than on drugs given. This protects the evaluation process from commercial influences and allows a fair comparison of old- versus new-generation psoriasis treatments. In contrast to the patients in a registry who receive care in the natural clinical setting, subjects in randomized clinical trials (RCTs) are selected according to study criteria and may therefore not reflect the experience of patients in clinical practice. It is possible that particular risks and opportunities in the real patient population may therefore go undetected in RCTs.Keywords
This publication has 7 references indexed in Scilit:
- Lymphoma Rates Are Low but Increased in Patients With PsoriasisArchives of Dermatology, 2003
- Association of Funding and Conclusions in Randomized Drug TrialsJAMA, 2003
- Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatientsEuropean Journal of Epidemiology, 2003
- Sponsorship, authorship, and accountabilityThe Lancet, 2001
- Pharmacoeconomic Evaluation in the Real WorldPharmacoEconomics, 1999
- Disease concomitance in psoriasisJournal of the American Academy of Dermatology, 1995
- Malignant tumors in patients with psoriasisJournal of the American Academy of Dermatology, 1992